El Refaey H - Search Results

1

Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease.

Ebadi M, Brown-Borg H, El Refaey H, Singh BB, Garrett S, Shavali S, Sharma SK. Ebadi M, et al. Among authors: el refaey h. Brain Res Mol Brain Res. 2005 Mar 24;134(1):67-75. doi: 10.1016/j.molbrainres.2004.09.011. Brain Res Mol Brain Res. 2005. PMID: 15790531 Free PMC article. Review.

2

Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson's disease and the neuroprotective role of coenzyme Q10.

Sharma SK, El Refaey H, Ebadi M. Sharma SK, et al. Among authors: el refaey h. Brain Res Bull. 2006 Jun 15;70(1):22-32. doi: 10.1016/j.brainresbull.2005.11.019. Epub 2005 Dec 27. Brain Res Bull. 2006. PMID: 16750479

3

Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins.

Ebadi M, Sharma SK, Ghafourifar P, Brown-Borg H, El Refaey H. Ebadi M, et al. Among authors: el refaey h. Methods Enzymol. 2005;396:276-98. doi: 10.1016/S0076-6879(05)96024-2. Methods Enzymol. 2005. PMID: 16291239

4

Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases.

Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, El ReFaey H, Carlson EC. Ebadi M, et al. Among authors: el refaey h. Curr Drug Targets. 2006 Nov;7(11):1513-29. doi: 10.2174/1389450110607011513. Curr Drug Targets. 2006. PMID: 17100591 Review.

5

Neuroprotective actions of selegiline.

Ebadi M, Sharma S, Shavali S, El Refaey H. Ebadi M, et al. Among authors: el refaey h. J Neurosci Res. 2002 Feb 1;67(3):285-9. doi: 10.1002/jnr.10148. J Neurosci Res. 2002. PMID: 11813232 Review.

6

Neuroprotective actions of coenzyme Q10 in Parkinson's disease.

Sharma S, Kheradpezhou M, Shavali S, El Refaey H, Eken J, Hagen C, Ebadi M. Sharma S, et al. Among authors: el refaey h. Methods Enzymol. 2004;382:488-509. doi: 10.1016/S0076-6879(04)82027-5. Methods Enzymol. 2004. PMID: 15047119 Review. No abstract available.

7

The antioxidant properties of zinc and metallothionein.

Ebadi M, Leuschen MP, el Refaey H, Hamada FM, Rojas P. Ebadi M, et al. Among authors: el refaey h. Neurochem Int. 1996 Aug;29(2):159-66. doi: 10.1016/0197-0186(95)00116-6. Neurochem Int. 1996. PMID: 8837045

8

Identification of metallothionein receptors in human astrocytes.

El Refaey H, Ebadi M, Kuszynski CA, Sweeney J, Hamada FM, Hamed A. El Refaey H, et al. Neurosci Lett. 1997 Aug 15;231(3):131-4. doi: 10.1016/s0304-3940(97)00548-x. Neurosci Lett. 1997. PMID: 9300639

9

Treatment with escitalopram but not desipramine decreases escape latency times in a learned helplessness model using juvenile rats.

Reed AL, Anderson JC, Bylund DB, Petty F, El Refaey H, Happe HK. Reed AL, et al. Among authors: el refaey h. Psychopharmacology (Berl). 2009 Aug;205(2):249-59. doi: 10.1007/s00213-009-1535-2. Epub 2009 Apr 22. Psychopharmacology (Berl). 2009. PMID: 19387616

10

BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53.

Basma H, El-Refaey H, Sgagias MK, Cowan KH, Luo X, Cheng PW. Basma H, et al. Among authors: el refaey h. J Biomed Sci. 2005 Dec;12(6):999-1011. doi: 10.1007/s11373-005-9025-y. Epub 2005 Oct 14. J Biomed Sci. 2005. PMID: 16228292

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters